A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 20,700 shares of DYN stock, worth $494,937. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,700
Previous 8,400 146.43%
Holding current value
$494,937
Previous $296,000 151.01%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$31.94 - $47.04 $44 Million - $64.8 Million
-1,376,666 Reduced 31.9%
2,939,340 $106 Million
Q2 2024

Aug 14, 2024

BUY
$23.65 - $35.63 $1.46 Million - $2.2 Million
61,730 Added 1.45%
4,316,006 $152 Million
Q1 2024

May 15, 2024

BUY
$13.06 - $29.18 $15.7 Million - $35 Million
1,200,836 Added 39.33%
4,254,276 $121 Million
Q4 2023

Feb 14, 2024

BUY
$6.62 - $13.64 $78,341 - $161,415
11,834 Added 0.39%
3,053,440 $40.6 Million
Q3 2023

Nov 14, 2023

BUY
$8.6 - $12.18 $2.89 Million - $4.09 Million
335,603 Added 12.4%
3,041,606 $27.3 Million
Q2 2023

Aug 14, 2023

SELL
$8.53 - $14.28 $2.75 Million - $4.61 Million
-322,797 Reduced 10.66%
2,706,003 $30.4 Million
Q1 2023

May 15, 2023

BUY
$10.88 - $15.0 $1.29 Million - $1.78 Million
118,721 Added 4.08%
3,028,800 $34.9 Million
Q4 2022

Feb 14, 2023

SELL
$9.37 - $13.8 $115,185 - $169,643
-12,293 Reduced 0.42%
2,910,079 $33.7 Million
Q3 2022

Nov 14, 2022

SELL
$7.2 - $15.17 $24,062 - $50,698
-3,342 Reduced 0.11%
2,922,372 $37.1 Million
Q2 2022

Aug 15, 2022

SELL
$4.36 - $10.5 $159,658 - $384,499
-36,619 Reduced 1.24%
2,925,714 $20.1 Million
Q1 2022

May 16, 2022

BUY
$6.52 - $12.27 $639,827 - $1.2 Million
98,133 Added 3.43%
2,962,333 $28.6 Million
Q4 2021

Feb 14, 2022

SELL
$11.89 - $16.07 $112,681 - $152,295
-9,477 Reduced 0.33%
2,864,200 $34.1 Million
Q3 2021

Nov 15, 2021

SELL
$15.6 - $21.46 $668,257 - $919,282
-42,837 Reduced 1.47%
2,873,677 $46.7 Million
Q2 2021

Aug 16, 2021

SELL
$15.94 - $22.33 $2.85 Million - $4 Million
-179,066 Reduced 5.78%
2,916,514 $61.4 Million
Q1 2021

May 17, 2021

SELL
$14.0 - $29.3 $962,360 - $2.01 Million
-68,740 Reduced 2.17%
3,095,580 $48.1 Million
Q4 2020

Feb 16, 2021

BUY
$16.81 - $23.94 $3.29 Million - $4.69 Million
195,927 Added 6.6%
3,164,320 $66.5 Million
Q3 2020

Nov 16, 2020

BUY
$20.0 - $23.9 $59.4 Million - $70.9 Million
2,968,393 New
2,968,393 $59.9 Million

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.24B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.